CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the...
Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb). )
Also on site :
- Wyndham Clark Loses Temper, Goes Berserk in U.S. Open Locker Room
- 7 Best Dresses for Women Over 60, According to Professional Stylists
- Iran’s Revolutionary Guard Corps mourns 7 commanders killed in recent Israeli attack